Effect of dorzolamide drop with intravitreal avastin injection in decreasing central macular thickness

Phase 2

Conditions: Edema macula.
Other specified disorders of eye and adnexa in diseases classified elsewhere
H58.8

Registration Number: IRCT20131229015975N5

Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 16

Inclusion Criteria

Diabetic patients with retinopathy who have macular edema due to increased macular thickness or vision loss are indicative of anti-VEGF treatment.
A transparent mediator for a thorough examination
Visual activity of both eyes are better than 1/10 and less than 4/10
Patient consent to Participate in the Study
The thickness of the central area of the macula at the start of treatment is greater than 300 microns

Exclusion Criteria

History of bone surgery
The presence of atrophy, scarring, fibrosis and hard exudates in the macular center that affects visual acuity.
Uncontrolled blood pressure
Presence of active eye infectious disease
There are other complications of diabetes in the eyes, which leads to an increase in the thickness of the macula.
The presence of other synchronous eye pathologies such as glaucoma and cataracts.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Visual activity. Timepoint: Before and two months after the intervention. Method of measurement: Examination by ophthalmologist.;Foie thickness. Timepoint: Before and two months after the intervention. Method of measurement: Optical Coherence Topography and Examination by ophthalmologist.;Macular volume. Timepoint: Before and two months after the intervention. Method of measurement: Optical Coherence Topography and Examination by ophthalmologist.

Secondary Outcome Measures